Cdk1 - cyclin-dependent kinase 1 Gene

中文名称：细胞周期蛋白依赖性激酶 1

种属: Rattus norvegicus

同用名: Cdc2; Cdc2a

基因 ID: 54237 | 基因类型: protein coding

关于 Cdk1

Biased expression in Thymus (RPKM 28.3), Spleen (RPKM 193.1) and 8 other tissues.

功能概要

该基因编码的蛋白可启动细胞周期蛋白结合活性；细胞周期蛋白依赖性蛋白丝氨酸/苏氨酸激酶活性；和组蛋白激酶活性。参与多个过程，包括高尔基体分解；蛋白质输入细胞核的正调节；和心室心肌细胞的发育。在基因表达的负调控上游或负调控中起作用。位于细胞质和细胞核中。肝细胞癌的生物标志物。该基因与乳腺癌相关的人类直向同源基因；宫颈癌;和膀胱癌。与人 CDK1（细胞周期蛋白依赖性激酶 1）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables cyclin binding activity; cyclin-dependent protein serine/threonine kinase activity; and histone kinase activity. Involved in several processes, including Golgi disassembly; positive regulation of protein import into nucleus; and ventricular cardiac muscle cell development. Acts upstream of or within negative regulation of gene expression. Located in cytoplasm and nucleus. Biomarker of hepatocellular carcinoma. Human ortholog(s) of this gene implicated in breast cancer; cervical cancer; and urinary bladder Cancer. Orthologous to human CDK1 (cyclin dependent kinase 1). [provided by Alliance of Genome Resources, Apr 2022]

Cdk1 基因产物(1)

mRNA	Protein	Name
NM_019296.2	NP_062169.1	cyclin-dependent kinase 1

基因本体论

分子功能
生物过程

分子功能 GO 注释	逻辑证据	参考文献	来源
enables cyclin binding	IPI IPI: 通过物理相互作用推断	15696186	RGD
enables cyclin-dependent protein serine/threonine kinase activity	IDA IDA: 通过直接分析推断	9753325	RGD
enables histone kinase activity	IDA IDA: 通过直接分析推断	19821535	RGD
enables protein binding	IPI IPI: 通过物理相互作用推断	9753325	RGD

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in Golgi disassembly	IDA IDA: 通过直接分析推断	9753325	RGD
involved in animal organ regeneration	IMP IMP: 通过突变表型推断	15696186	RGD
involved in cellular response to hydrogen peroxide	IEP IEP: 通过表达模式推断	16179908	RGD
involved in cellular response to organic cyclic compound	IDA IDA: 通过直接分析推断	15695611	RGD
involved in chromosome condensation	IMP IMP: 通过突变表型推断	15695611	RGD
acts upstream of or within negative regulation of gene expression	IMP IMP: 通过突变表型推断	28350193	RGD
involved in peptidyl-serine phosphorylation	IDA IDA: 通过直接分析推断	9753325	RGD
involved in positive regulation of DNA replication	IMP IMP: 通过突变表型推断	19821535	RGD
involved in positive regulation of cardiac muscle cell proliferation	IMP IMP: 通过突变表型推断	15253691	RGD
acts upstream of positive regulation of gene expression	IMP IMP: 通过突变表型推断	28350193	RGD
involved in positive regulation of gene expression	IMP IMP: 通过突变表型推断	18356527	RGD
involved in positive regulation of mitotic cell cycle	IMP IMP: 通过突变表型推断	15696186	RGD
involved in positive regulation of protein import into nucleus	IMP IMP: 通过突变表型推断	18356527	RGD
involved in protein-containing complex assembly	IDA IDA: 通过直接分析推断	19136513	RGD
involved in response to activity	IEP IEP: 通过表达模式推断	16826023	RGD
involved in response to amine	IEP IEP: 通过表达模式推断	16155410	RGD
involved in response to axon injury	IEP IEP: 通过表达模式推断	17200138	RGD
involved in response to cadmium ion	IEP IEP: 通过表达模式推断	16730872	RGD
involved in response to copper ion	IEP IEP: 通过表达模式推断	19497425	RGD
involved in response to ethanol	IDA IDA: 通过直接分析推断	18181150	RGD
involved in response to hydrogen peroxide	IEP IEP: 通过表达模式推断	16963227	RGD
involved in response to organic cyclic compound	IEP IEP: 通过表达模式推断	16427046	RGD
involved in response to toxic substance	IEP IEP: 通过表达模式推断	19237604	RGD
involved in response to xenobiotic stimulus	IEP IEP: 通过表达模式推断	16427046	RGD
involved in ventricular cardiac muscle cell development	IEP IEP: 通过表达模式推断	15253691	RGD

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Cdk1 蛋白结构

STKc_CDK1_euk

0
100
200
297 a.a.

蛋白主名

其他名称

cyclin-dependent kinase 1

Cell division cycle control protein 2	cell division control protein 2 homolog
cell division cycle 2 homolog A	cell division cycle 2, G1 to S and G2 to M
cell division protein kinase 1	p34 protein kinase

相关产品

Approval

生物活性分子 (4)

目录号	产品名	作用方式	纯度	是否罕见病
HY-16297A	Abemaciclib	Inhibitor	99.97%	是
HY-10492	Dinaciclib	Inhibitor	99.36%	是
HY-16297	Abemaciclib methanesulfonate	Inhibitor	99.95%	是
HY-B0263	Thiabendazole	Inhibitor	99.77%	否

Clinical Phase

生物活性分子 (27)

目录号	产品名	作用方式	纯度	Phase
HY-10580	GSK 3 Inhibitor IX	Inhibitor	99.74%	Phase 4
HY-112272	Lerociclib	Inhibitor	98.35%	Phase 3
HY-10005	Flavopiridol	Inhibitor	99.73%	Phase 2
HY-30237	(R)-Roscovitine	Inhibitor	99.84%	Phase 2
HY-103712A	Samuraciclib hydrochloride	Inhibitor	99.98%	Phase 2
HY-50940	AT7519	Inhibitor	99.76%	Phase 2
HY-10006	Flavopiridol Hydrochloride	Inhibitor	99.73%	Phase 2
HY-13914	Roniciclib	Inhibitor	98.09%	Phase 2
HY-10424	Milciclib	Inhibitor	99.90%	Phase 2
HY-112272A	Lerociclib dihydrochloride	Inhibitor	98.11%	Phase 2
HY-16559	Riviciclib hydrochloride		98.89%	Phase 2
HY-103712B	Samuraciclib hydrochloride dihydrate	Inhibitor	99.08%	Phase 2
HY-137432	Avotaciclib	Inhibitor	99.72%	Phase 2
HY-50943	AT7519 Hydrochloride	Inhibitor	99.42%	Phase 2
HY-137432A	Avotaciclib trihydrochloride	Inhibitor	99.75%	Phase 2
HY-103712C	Samuraciclib hydrochloride hydrate	Inhibitor	99.88%	Phase 2
HY-103712	Samuraciclib	Inhibitor	/	Phase 2
HY-16559A	Riviciclib	Inhibitor	/	Phase 2
HY-10008	SNS-032	Inhibitor	99.54%	Phase 1
HY-10012	AZD-5438	Inhibitor	99.85%	Phase 1
HY-12871B	Atuveciclib	Inhibitor	99.80%	Phase 1
HY-11001	PHA-793887	Inhibitor	99.25%	Phase 1
HY-15504	RGB-286638	Inhibitor	99.70%	Phase 1
HY-12422	Voruciclib	Inhibitor	99.77%	Phase 1
HY-15504A	RGB-286638 free base	Inhibitor	98.07%	Phase 1
HY-12422A	Voruciclib hydrochloride	Inhibitor	99.23%	Phase 1
HY-50940A	AT7519 TFA	Inhibitor	98.53%	Phase 1

Pre-clinical Phase

生物活性分子 (85)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-12529	Ro-3306	Inhibitor	98.68%	否
HY-12302	Kenpaullone	Inhibitor	98.20%	否
HY-10329	JNJ-7706621	Inhibitor	99.91%	否
HY-124719	hSMG-1 inhibitor 11j	Inhibitor	99.82%	否
HY-15339	CVT-313	Inhibitor	99.90%	否
HY-15154	NG 52	Inhibitor	99.97%	否
HY-18340	(R)-CR8	Inhibitor	99.61%	否
HY-11009	CGP60474	Inhibitor	99.23%	否
HY-124760	hSMG-1 inhibitor 11e	Inhibitor	99.81%	否
HY-N0417	Cucurbitacin E	Inhibitor	99.92%	否
HY-10032	PF 477736	Inhibitor	99.21%	否
HY-18299A	Purvalanol A	Inhibitor	98.30%	否
HY-15878	LDC000067	Inhibitor	98.09%	否
HY-10014	R547	Inhibitor	99.57%	否
HY-15275	BMS-265246	Inhibitor	98.92%	否
HY-12445	Asnuciclib	Inhibitor	99.76%	否
HY-13461A	PHA-767491 hydrochloride	Inhibitor	99.49%	否
HY-18340A	(R)-CR8 trihydrochloride	Inhibitor	98.95%	否
HY-13266A	BS-181 hydrochloride	Inhibitor	99.80%	否
HY-18629	SU9516	Inhibitor	99.81%	否
HY-12280	THZ2	Inhibitor	99.03%	否
HY-X0150	JSH-150	Inhibitor	98.36%	否
HY-117535	CDK2-IN-4	Inhibitor	96.71%	否
HY-18299	Purvalanol B	Inhibitor	≥97.0%	否
HY-119940	MC180295	Inhibitor	98.89%	否
HY-129478	TC11	Activator	98.04%	否
HY-15569	NU6102	Inhibitor	99.23%	否
HY-15889	AMG 925	Inhibitor	98.20%	否
HY-108359	Alsterpaullone	Inhibitor	99.85%	否
HY-148062	RSS0680		98.03%	否
HY-103647	K00546	Inhibitor	98.08%	否
HY-103221	MeBIO	Inhibitor	≥98.0%	否
HY-107419	NU6140	Inhibitor	99.07%	否
HY-139980	CDK9-IN-13	Inhibitor	99.94%	否
HY-112463	CDK1-IN-2	Inhibitor	97.17%	否
HY-19316	NU2058	Inhibitor	99.66%	否
HY-15241	NVP-LCQ195	Inhibitor	98.81%	否
HY-100429	CAN508	Inhibitor	99.59%	否
HY-111237	Butyrolactone I	Inhibitor	98.03%	否
HY-153556	GW297361	Inhibitor	98.13%	否
HY-N5072	Desmethylglycitein	Inhibitor	98.98%	否
HY-13816	NU6027	Inhibitor	99.04%	否
HY-111930	5-Iodo-indirubin-3'-monoxime	Inhibitor	99.50%	否
HY-112462	Cdk1/2 Inhibitor III	Inhibitor	99.69%	否
HY-115924	CDK1-IN-1	Inhibitor	99.33%	否
HY-103383	(R)-DRF053 dihydrochloride	Inhibitor	99.30%	否
HY-N12625	(R)-(+)-O-Demethylbuchenavianine	Inhibitor	98.67%	否
HY-103381	NSC693868	Inhibitor	≥99.0%	否
HY-112346	RGB-286147	Inhibitor	98.60%	否
HY-136726	CGP-82996	Inhibitor	98.12%	否
HY-13266	BS-181	Inhibitor	98.10%	否
HY-14372	BS-194	Inhibitor	99.36%	否
HY-X0009A	JSH-009 dimaleate	Inhibitor	/	否
HY-114903	(E/Z)-BIO-acetoxime	Inhibitor	/	否
HY-15889A	AMG 925 HCl	Inhibitor	/	否
HY-13461	PHA-767491	Inhibitor	99.85%	否
HY-151407	CDK1-IN-3	Inhibitor	/	否
HY-151409	CDK1-IN-5	Inhibitor	/	否
HY-126244	CDK4/6-IN-3	Inhibitor	/	否
HY-141685	3-Methylthienyl-carbonyl-JNJ-7706621	Inhibitor	/	否
HY-115942	Anticancer agent 29	Inhibitor	/	否
HY-123034	CDKI-83	Inhibitor	/	否
HY-112363	Aloisine A	Inhibitor	/	否
HY-142696	CDK6/PIM1-IN-1	Inhibitor	/	否
HY-161826	Antitumor agent-174	Inhibitor	/	否
HY-155787	SHR5428	Inhibitor	/	否
HY-147901	KDM1/CDK1-IN-1	Inhibitor	/	否
HY-146276	CDK/HDAC-IN-2	Inhibitor	/	否
HY-151408	CDK1-IN-4	Inhibitor	/	否
HY-163856	CDK7-IN-30	Inhibitor	/	否
HY-123369	BMI-1026	Inhibitor	/	否
HY-151071	TMX-3013	Inhibitor	/	否
HY-168673	CDK1-IN-6	Inhibitor	/	否
HY-146253	CDK1/2/4-IN-1	Inhibitor	/	否
HY-151878	CDK7-IN-20	Inhibitor	/	否
HY-147646	CDK1/Cyc B-IN-1	Inhibitor	98.47%	否
HY-112336	Aloisine RP106	Inhibitor	/	否
HY-151898	CDK4/6-IN-14	Inhibitor	/	否
HY-112403	(S)-Roscovitine	Inhibitor	/	否
HY-160643	CDK2-IN-27	Inhibitor	/	否
HY-123045	PNU-292137	Inhibitor	/	否
HY-112450	Olomoucine II	Inhibitor	/	否
HY-112394	2-Cyanoethylalsterpaullone	Inhibitor	/	否
HY-111932	Indirubin-5-sulfonate	Inhibitor	/	否
HY-111931	Indirubin-3'-monoxime-5-sulphonic acid	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Cdk1	NCBI	NCBI:983
Mus musculus	Cdk1	NCBI	NCBI:12534

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4